Fig. 1: RRM2, not RRM2B, is associated with HB progression in mice and patients.
From: Ribonucleotide reductase subunit switching in hepatoblastoma drug response and relapse
a Schematic illustration (created with BioRender.com) showing the establishment of PNR genetic mouse model, organoid model, and orthotopic allograft models. b Quantitative comparison of the gene expression of the three RNR subunits in PNR tumor tissues (n = 6, 9, 6, 3, and 7 for the five indicated groups, respectively) and organoids (n = 6, 17, and 4 for the three indicated groups, respectively). c Expression of the three RNR subunits in the control liver (n = 6) and pathologically-defined HB patient risk groups (low, medium, and high; n = 15, 13, and 19, respectively) and molecularly-defined risk groups (HB1, HB3, and HB2 from low- to high-risk; n = 15, 15, and 16, respectively) from a publicly available HB transcriptomics database24. d H&E staining (i–iii), RNAscope staining for RRM2 (iv–vi) and RRM2B (vii–ix), and Ki67 IHC staining (x–xii) on the serial sections of three HB PDX tumors. All images share the same 200 μm scale bar in (xii). Insets in (iv–ix): higher magnification images of the corresponding RNAscope staining and share the 20 μm scale bar in the inset in (ix). Student t test: P values: * <0.05; ** <0.01; *** <0.001; **** <0.0001.
